# Prevalence of Splanchnic Vein Thrombosis in Pancreatitis: A Systematic Review and Meta-Analysis of Observational Studies

Authors: Wenda Xu; Xingshun Qi; Jiang Chen; Chunping Su; Xiaozhong Guo
Journal: Gastroenterology Research and Practice
 (2015)

---

## Abstract

Splanchnic vein thrombosis (SVT) may be negatively associated with the prognosis of pancreatitis. We performed a systematic review and meta-analysis of literatures to explore the prevalence of SVT in pancreatitis. All observational studies regarding the prevalence of SVT in pancreatitis were identified via PubMed and EMBASE databases. The prevalence of SVT was pooled in the total of patients with pancreatitis. And it was also pooled in the subgroup analyses according to the stage and causes of pancreatitis, location of SVT, and regions where the studies were performed. After the review of 714 studies, 44 studies fulfilled the inclusion criteria. Meta-analyses showed a pooled prevalence of SVT of 13.6% in pancreatitis. According to the stage of pancreatitis, the pooled prevalence of SVT was 16.6% and 11.6% in patients with acute and chronic pancreatitis, respectively. According to the causes of pancreatitis, the pooled prevalence of SVT was 12.2% and 14.6% in patients with hereditary and autoimmune pancreatitis. According to the location of SVT, the pooled prevalence of portal vein, splenic vein, and mesenteric vein thrombosis was 6.2%, 11.2%, and 2.7% in pancreatitis. The prevalence of SVT in pancreatitis was 16.9%, 11.5%, and 8.5% in Europe, America, and Asia, respectively.


---

## Body

## 1. Introduction

Splanchnic vein thrombosis (SVT) is one such vascular complication of pancreatitis. SVT involves the portal vein (PV), splenic vein (SplV), and mesenteric vein (MV) with the occurrence in combination or separately [1]. The consequence of pancreatitis-induced SVT may generate a localized form of portal hypertension and then splenoportal or gastroepiploic systems burden following localized venous hypertension and lead to gastric, oesophageal, or colonic varices. It may also cause the liver failure, bowel ischemia, and gastrointestinal bleeding [2]. Patients suffer from great pain and potentially lethal threaten. The limited literature cannot acquire an exact prevalence of SVT in pancreatitis. The aim of the present systematic review and meta-analysis is to obtain the prevalence of SVT in pancreatitis by resolving the following three questions. (1) What is the prevalence of SVT in pancreatitis, including PVT, SplVT, and MVT? (2) What is the prevalence of SVT in different types of pancreatitis? (3) What is the prevalence of SVT in pancreatitis in different regions? This study is conducted according to the guidelines for the reporting of meta-analysis of observational studies, which were published by the Meta-analysis of Observational Studies in Epidemiology Group in 2000 [3].


## 2. Methods

As a systematic review and meta-analysis were planned, we reviewed standard guidelines to conduct meta-analysis studies according to a protocol determined before the study, including study objectives, prespecified eligibility criteria, and methods of statistical analysis.


### 2.1. Eligibility Criteria

(1)
The participants of any age were diagnosed with pancreatitis, including acute pancreatitis (AP), chronic pancreatitis (CP), hereditary pancreatitis (HP), or autoimmune pancreatitis (AIP). The participants with underlying malignancy, cirrhosis, trauma, abdominal surgery unrelated to ongoing pancreatitis, pregnancy, intra-abdominal infections, primary myeloproliferative disorders, or other pancreatic diseases or pancreatitis and resultant SVT were not deliberately excluded.
(2)
All cohort and case-control studies were eligible, regardless of the retrospective or prospective nature of the study; case reports were excluded.
(3)
Reviews, comments, or letters on the relationship of pancreatitis and SVT were excluded.
(4)
Animal studies were also excluded.
(5)
There was no publication date or publication status restrictions.
(6)
There were no language restrictions.
(7)
The number of participants in any included study was beyond 10.


### 2.2. Search Strategy

The MEDLINE and EMBASE databases were searched using a search strategy from their inception to July 2014. Search items combined keywords and medical subject heading terms (MeSH) were listed as follows: (“pancreatitis” (MeSH Terms) or “pancreatitis” (All Fields)) and ((“portal vein” (MeSH Terms) or (“portal” (All Fields) and “vein” (All Fields)) or “portal vein” (All Fields)) and (“thrombosis” (MeSH Terms) or “thrombosis” (All Fields))) or ((“splenic vein” (MeSH Terms) or (“splenic” (All Fields) and “vein” (All Fields)) or “splenic vein” (All Fields)) and (“thrombosis” (MeSH Terms) or “thrombosis” (All Fields))) or ((“mesenteric veins” (MeSH Terms) or (“mesenteric” (All Fields) and “veins” (All Fields)) or “mesenteric veins” (All Fields) or (“mesenteric” (All Fields) and “vein” (All Fields)) or “mesenteric vein” (All Fields)) and (“thrombosis” (MeSH Terms) or “thrombosis” (All Fields))). The last search was performed on July 29, 2014. The reference lists of the included articles were further hand-searched to identify any additional relevant studies. When the same data were found in more than one publication, only the studies with more complete data and more extensive interval of enrolment were included in the meta-analysis. Full-texts were found by three investigators (Wenda Xu, Xingshun Qi, and Chunping Su).


### 2.3. Data Extraction

Using a predefined protocol, two investigators (Wenda Xu and Xingshun Qi) independently reviewed the titles and abstracts of all references to identify studies for inclusion in the analysis. Dealing with disagreement between the two reviewers, a consensus was achieved through discussion among all of the reviewers. A schematic diagram depicting reference flow is shown through the systematic review process. Additionally, a data extraction sheet was generated that included authors, publication year, study design, country where the study was conducted, period of enrolment, inclusion and exclusion criteria, type of diseases (AP, CP, HP, or AIP), total sample size, demographic data (age and gender), number of patients with PVT, SplV, or MVT, and proportion of patients with PVT, SplV, or MVT, respectively.


### 2.4. Evaluation of Study Quality

Quality assessment of studies was carried out independently by two reviewers (Wenda Xu and Xingshun Qi). Discrepancies of interpretation and comprehension were resolved by consensus. The higher quality studies should fulfill the following predetermined criteria.(1)
Country where the study was conducted, interval of enrolment, inclusion and exclusion criteria, and participant characteristics (age, gender) were clearly recorded.
(2)
Pancreatitis was diagnosed on the basis of history, clinical manifestations, elevated serum lipase and amylase, imaging detection by ultrasonography (US), endoscopic ultrasonography (EUS), computed tomography (CT), magnetic resonance imaging (MRI), or endoscopic retrograde cholangiopancreatography (ERCP), and/or typical histopathology.


### 2.5. Data Synthesis and Statistical Analysis

The proportion of pancreatitis patients with SVT in each study was combined to give a pooled prevalence of SVT for all studies. With this method, the pooled prevalence of PVT, SplV, and MVT was calculated. Furthermore, according to the type of pancreatitis and continents (Europe, America, and Asia), the pooled prevalence of SVT, PVT, SplV, and MVT was also created. The number and crude proportion of participants with SVT recorded by each study were used to pool the overall proportion, using the DerSimonian-Laird random-effects method. Between-study heterogeneity was assessed by using theI
2 index (I
2
>
50% was considered having substantial heterogeneity) and the Chi-squared test (P
<
0
.
01 was considered representing significant statistical heterogeneity) [4]. Individualized random effects meta-analyses were performed to estimate percentages and 95% confidence intervals (CIs) for all endpoints queried. Analyses were conducted using StatsDirect statistical software version 2.7.8 (StatsDirect Ltd, Sale, Cheshire, UK).


## 2.1. Eligibility Criteria

(1)
The participants of any age were diagnosed with pancreatitis, including acute pancreatitis (AP), chronic pancreatitis (CP), hereditary pancreatitis (HP), or autoimmune pancreatitis (AIP). The participants with underlying malignancy, cirrhosis, trauma, abdominal surgery unrelated to ongoing pancreatitis, pregnancy, intra-abdominal infections, primary myeloproliferative disorders, or other pancreatic diseases or pancreatitis and resultant SVT were not deliberately excluded.
(2)
All cohort and case-control studies were eligible, regardless of the retrospective or prospective nature of the study; case reports were excluded.
(3)
Reviews, comments, or letters on the relationship of pancreatitis and SVT were excluded.
(4)
Animal studies were also excluded.
(5)
There was no publication date or publication status restrictions.
(6)
There were no language restrictions.
(7)
The number of participants in any included study was beyond 10.


## 2.2. Search Strategy

The MEDLINE and EMBASE databases were searched using a search strategy from their inception to July 2014. Search items combined keywords and medical subject heading terms (MeSH) were listed as follows: (“pancreatitis” (MeSH Terms) or “pancreatitis” (All Fields)) and ((“portal vein” (MeSH Terms) or (“portal” (All Fields) and “vein” (All Fields)) or “portal vein” (All Fields)) and (“thrombosis” (MeSH Terms) or “thrombosis” (All Fields))) or ((“splenic vein” (MeSH Terms) or (“splenic” (All Fields) and “vein” (All Fields)) or “splenic vein” (All Fields)) and (“thrombosis” (MeSH Terms) or “thrombosis” (All Fields))) or ((“mesenteric veins” (MeSH Terms) or (“mesenteric” (All Fields) and “veins” (All Fields)) or “mesenteric veins” (All Fields) or (“mesenteric” (All Fields) and “vein” (All Fields)) or “mesenteric vein” (All Fields)) and (“thrombosis” (MeSH Terms) or “thrombosis” (All Fields))). The last search was performed on July 29, 2014. The reference lists of the included articles were further hand-searched to identify any additional relevant studies. When the same data were found in more than one publication, only the studies with more complete data and more extensive interval of enrolment were included in the meta-analysis. Full-texts were found by three investigators (Wenda Xu, Xingshun Qi, and Chunping Su).


## 2.3. Data Extraction

Using a predefined protocol, two investigators (Wenda Xu and Xingshun Qi) independently reviewed the titles and abstracts of all references to identify studies for inclusion in the analysis. Dealing with disagreement between the two reviewers, a consensus was achieved through discussion among all of the reviewers. A schematic diagram depicting reference flow is shown through the systematic review process. Additionally, a data extraction sheet was generated that included authors, publication year, study design, country where the study was conducted, period of enrolment, inclusion and exclusion criteria, type of diseases (AP, CP, HP, or AIP), total sample size, demographic data (age and gender), number of patients with PVT, SplV, or MVT, and proportion of patients with PVT, SplV, or MVT, respectively.


## 2.4. Evaluation of Study Quality

Quality assessment of studies was carried out independently by two reviewers (Wenda Xu and Xingshun Qi). Discrepancies of interpretation and comprehension were resolved by consensus. The higher quality studies should fulfill the following predetermined criteria.(1)
Country where the study was conducted, interval of enrolment, inclusion and exclusion criteria, and participant characteristics (age, gender) were clearly recorded.
(2)
Pancreatitis was diagnosed on the basis of history, clinical manifestations, elevated serum lipase and amylase, imaging detection by ultrasonography (US), endoscopic ultrasonography (EUS), computed tomography (CT), magnetic resonance imaging (MRI), or endoscopic retrograde cholangiopancreatography (ERCP), and/or typical histopathology.


## 2.5. Data Synthesis and Statistical Analysis

The proportion of pancreatitis patients with SVT in each study was combined to give a pooled prevalence of SVT for all studies. With this method, the pooled prevalence of PVT, SplV, and MVT was calculated. Furthermore, according to the type of pancreatitis and continents (Europe, America, and Asia), the pooled prevalence of SVT, PVT, SplV, and MVT was also created. The number and crude proportion of participants with SVT recorded by each study were used to pool the overall proportion, using the DerSimonian-Laird random-effects method. Between-study heterogeneity was assessed by using theI
2 index (I
2
>
50% was considered having substantial heterogeneity) and the Chi-squared test (P
<
0
.
01 was considered representing significant statistical heterogeneity) [4]. Individualized random effects meta-analyses were performed to estimate percentages and 95% confidence intervals (CIs) for all endpoints queried. Analyses were conducted using StatsDirect statistical software version 2.7.8 (StatsDirect Ltd, Sale, Cheshire, UK).


## 3. Results

### 3.1. Description of the Included Studies

In the initial search strategy, a total of 947 studies were selected. Among them, 714 studies were retrieved by removing duplicate research. Two additional unique references were found through reference lists of an original article and a review, respectively [5, 6]. One study as object of related comment was also identified [7]. Total of 44 studies were included in the meta-analysis (Figure 1). Additionally, five studies recorded by the same study team in different publications were excluded [8–12] and one study which concerned the same patients by the same first author in different publications was also excluded [13]. Another study was excluded because the number of participants was <10 [14]. Twenty-two of 44 studies were conducted in Europe [6, 15–35], fourteen in America [2, 5, 7, 36–46], and eight in Asia [47–54]. Among 10441 participants, 874 patients with SVT were screened. These patients included 197 patients with PVT, 525 with SplV, and 72 with MVT. The detailed characteristics of these included studies were shown in Table 1.Table 1
Overview of included studies.
Authors         (publication year)
Type of research
Country
Interval of enrolment
Eligibility criteria
Type of disease  (AP, CP,  HP, or AIP)
Number of total samples
SVT
PVT
SlpVT
MVT
Mean age (range years)
Female/male
Sisman et al.(2014) [19]
Retrospectivecohort study
Turkey
2007–2011
NA
CP
65
13
NA
13
NA
NA
14/51
Britton et al.(2014) [18]
Retrospectivecohort study
UK
1998–2012
Exclusion criteria: 46 cases were excluded from the final analysis as imaging reports made no comment on the portal venous system.
AP
145
90
90
NA
NA
56.1
NA
Talukdar et al.(2014) [47]
Prospective cohort study
India
August 2011 to October 2012
Inclusion criteria: patients over 18 yrs with a primary diagnosis of first episode of AP from August 2011 to October 2012, and prospectively followed for at least six months after discharge or till death; exclusion criteria were (1) recurrent AP; (2) patient who did not get a CT scan.
AP
163
12
3
9
NA
NA
40/123
Easler et al.(2014) [38]
Prospective  study
USA
June 2003 and April 2010
Inclusion criteria: SAP patients who were admitted with their first AP attack; exclusion criteria:  patients with a history of AP or CP.
AP
162
22
8
19
6
55  ± 20
78/84
Castiñeira-Alvariño et al.(2013) [20]
Prospective study
Spain
Since 2007
Inclusion criteria: patients with age <18 years at index visit to the CP outpatient clinic; exclusion criteria: patients who clearly modified the diet before the index visit were excluded.
CP
168
5
5
NA
NA
44  (17–76)
40/128
Suero et al.(2013) [21]
Retrospective study
Spain
NA
NA
AIP
25
6
NA
NA
NA
(17–79)
2/23
Marra-López et al.(2013) [22]
Prospective  cohort study
Spain
2011–2013
Inclusion criteria: CP patients defined by M-ANNHEIM.
CP
85
9
NA
9/85
NA
59.38
17/68
Harris et al.(2013) [2]
Retrospective study
USA
January 1996 to December 2006
Inclusion criteria: an institutional  (Mayo clinic) database search was done using the key terms acute pancreatitis and superior mesenteric vein thrombosis  (SMVT), portal vein thrombosis  (PVT), and splenic vein thrombosis  (SplVT) from January 1996 to December 2006; exclusion criteria: (1) patients with precipitating factors for thrombosis  (abdominal surgery unrelated to ongoing pancreatitis, trauma, pregnancy, cirrhosis, intra-abdominal infections, pancreatic cancer, and primary myeloproliferative disorders) were excluded. (2) All cases of chronic pancreatitis were also excluded.
AP
2454
45
20
30
17
NA
NA
Jakchairoongruang and Arjhansiri(2013) [48]
Retrospective study
Thailand
January 1, 2005 and April 30, 2010
Exclusion criteria: six hundred and eight patients were excluded from the study population because of the following reasons: it was not the first episode of acute pancreatitis, the initial CT was not performed, there are no available CT images on our Pictures Archiving and Communications System  (PACS), or patient was imaged with only unenhanced CT.
AP
72
1
NA
1/72
NA
47.7 (6–89)
33/39
Ishikawa et al. (2012) [49]
Retrospective study
Japan
July 2003 and October 2010
Inclusion criteria: patients who met the International Consensus Diagnostic Criteria  (ICDC) for AIP.
AIP
54
1
1
NA
NA
63.2  ± 13.5  (28–86)
6/48
Sisman et al.(2012) [24]
Retrospective study
Turkey
2007–2011
Exclusion criteria: patients who received previous H. pylori eradication treatment and who are with any malignancy were excluded.
CP
64
11
NA
11
NA
NA
NA
De León et al.(2012) [25]
Retrospective study
Spain
NA
NA
AIP
16
4
NA
4
NA
46.6       (17–73)
1/15
Vyas et al.(2012) [23]
Retrospective study
UK
NA
NA
AP
87
22
NA
12
NA
NA
35/52
Muddana et al.(2012) [39]
Prospective  study
USA
2003–2010
NA
AP
251
41
NA
35
NA
51.5   ± 19
123/128
Rebours et al.(2012) [17]
Prospective single-center  study
France
2000–2009
Included criteria: all of the in- or outpatients with recurrent acute or chronic alcoholic pancreatitis and followed prospectively based on a standardized protocol, including a yearly physical examination and a search for exocrine pancreatic insufficiency, diabetes, and cholestasis; excluded criteria: (1) cirrhosis; (2) patients who were lost to follow-up in 2009.
AP or CP
119
41
14
38
10
NA
19/100
Gonzelez et al.(2011) [15]
Retrospective study
UK
January 1, 2008, and December 31, 2009
Excluded criteria: patients with chronic pancreatitis, known malignancy, cirrhosis, or established portal hypertension.
AP
127
20
10
14
3
53.5              (36–81)
118/9
Shalimar et al.(2011) [36]
Prospective  study
USA
NA
Inclusion criteria: patients with CP after an informed consent and ethical clearance; exclusion criteria: NA.
CP
226
9
NA
9
NA
NA
48/178
Huggett et al.(2011) [16]
Prospective  study
UK
2004–2010
Inclusion criteria: patients with AIP and with a median follow-up from diagnosis of 32 months  (range 0–76)
AIP
52
7
NA
NA
NA
59  (26–85)
11/41
Chowdhury et al.(2011) [50]
Retrospective study
India
January 2005 and December 2009
Inclusion criteria: children diagnosed with chronic pancreatitis  (on imaging study).
CP
73
4
NA
NA
NA
NA
22/51
Chooklin and Hranat (2009) [26]
Retrospective study
Ukraine
NA
NA
AP
20
4
NA
4
NA
NA
3/17
Vege et al.(2009) [37]
Retrospective study
USA
1989–2007
Exclusion criteria: patients with preexisting portal hypertension were excluded.
AP
1155
50
3
29
4
NA
NA
Keck et al.(2009) [27]
Retrospective study
Germany
In Germany: 2001–2005; in USA: 1995–2005
Excluded criteria: three patients whose predominant lesion was only a very dilated pancreatic duct and who were thus selected for lateral pancreaticojejunostomy.
CP
93
14
NA
14
NA
NA
31/62
Raina  et al.(2009) [5]
Retrospective study
USA
1998–2007
Exclusion criteria: three other malignancies (gastric cancer, the recurrence of gastric adenocarcinoma, and pancreatic adenocarcinoma).
AIP
26
4
NA
4
NA
62.5             (23–86)
9/17
Agarwal et al.(2008) [51]
Retrospective study
India
January 1996 and December 2005
NA
CP
157
34
NA
34
NA
NA
NA
Mortelé et al.(2004) [40]
Retrospective study
USA
17-month period
NA
AP
100
46
13
19
14
51             (12–80)
47/53
Makowiec et al.(2004) [28]
Prospective  study
Germany
1994–2001
Exclusion criteria: 12 patients with portal hypertension and 9 patients underwent splenectomy without splenic vein thrombosis.
CP
177
NA
NA
39
NA
NA
NA
Pimentel et al.(2003) [41]
Retrospective study
Brazil
1989–2002
NA
CP
64
2
NA
NA
NA
NA
14/50
Malíková et al.(2002) [29]
Retrospective study
Czech Republic
NA
NA
AP
40
NA
2
7
4
NA
NA
Mortelé et al.(2001) [42]
Retrospective study
USA
April 1996 and August 1997
NA
AP
100
19
NA
19
NA
NA
47/53
Sakorafas et al.(2000) [43]
Prospective  study
USA
1976–1997
NA
CP
484
34
NA
34
NA
NA
NA
Dörffel et al.(2000) [30]
Prospective  study
Germany
38 months
Included criteria: definite diagnosis of acute pancreatitis as detected by ultrasonography  (US) and CT, elevated serum lipase and amylase, compatible clinical picture, onset of pain symptoms not more than 3 days before admission, no history of pancreatitis, and no deficiencies in antithrombin III, protein C, and protein S.
AP
189
45
11
28
6
43             (19–80)
49/140
Arotcarena et al.(1999) [31]
Prospective  study
France
April 1993 to April 1996
NA
CP
494
73
NA
NA
NA
NA
NA
Tsushima et al.(1999) [52]
Retrospective study
Japan
April 1993 and August 1997
Included criteria: patients with AP  underwent initial abdominal CT within 3 days after the onset of symptoms and received at least one additional CT examination thereafter; Excluded criteria: cases of traumatic or postoperative pancreatitis
AP
25
1
NA
1
NA
53.4  ± 20.8                 (25–83)
7/18
Takase et al.(1997) [54]
Prospective  study
Japan
During the past 10 years
Exclusion criteria: 6 patients underwent pancreatoduodenectomy or biopsy without the splenic vein specimens
CP
12
5
NA
5
NA
48.8
0/12
Friess et al.(1997) [32]
Retrospective study
Greece
NA
NA
CP
397
21
NA
NA
NA
NA
NA
Lin et al.(1997) [53]
Prospective  study
Taiwan
1976–1996
NA
CP
90
5
NA
5
NA
NA
NA
Bernades et al.(1992) [6]
Prospective  longitudinal  Study
France
January  1980 and  March  1990
Inclusion criteria: patients who  met  the  criteria  of  CP and who had  been followed-up during observation; exclusion criteria: patients with cirrhosis.
CP
266
35
10
22
3
40.5              (6–77)
35/231
Nordback et al.  (1989) [35]
Retrospective study
Finland
1972–1986
NA
AP or CP
1268
6
2
2
4
NA
NA
Rogers and Klatt(1989) [44]
Retrospective  autopsy case-control  study
USA
January  1958  and  December  1987
Inclusion criteria: cases were included for  study if acute pancreatitis  was the  immediate or contributing cause  of  death  and  the  portal  venous  system   (both  splenic  and  portal  veins) was  examined  completely  at  autopsy. Exclusion criteria: patients  were  excluded  from  study  if there  had  been  a  splenectomy  or  if  chronic  pancreatitis  was  present  microscopically.
AP
72
11
NA
11
NA
NA
20/52
Hofer et al.(1987) [45]
Prospective  study
USA
1975–1985
NA
CP
50
11
NA
11
NA
50             (13–75)
24/26
Roesch et al.(1981) [33]
Retrospective study
Germany
NA
NA
CP
531
27
NA
27
NA
42.5
49/482
Sibert  (1978) [34]
Retrospective study
UK
NA
NA
HP
72
5
2
3
NA
NA
NA
McElroy and Christiansen(1972) [46]
Retrospective study
USA
NA
NA
HP
26
5
3
2
NA
NA
NA
Gross  (1958) [7]
Prospective  study
USA
1956
NA
AP or CP
125
2
NA
1
1
49              (6–75)
34/91
NA: the data are not available; AP: acute pancreatitis; CP: chronic pancreatitis; HP: hereditary pancreatitis; AIP: autoimmune pancreatitis; SVT: splanchnic vein thrombosis; PVT: portal vein thrombosis; SlpVT: splenic vein thrombosis; MVT: mesenteric vein thrombosis.Figure 1
Flow diagram of study selection.


### 3.2. Quality of the Included Studies

The involved countries of all studies could be found. Interval of enrolment was unavailable in ten of the 44 studies. Twenty-one studies had no eligibility criteria; eight of the remaining 23 studies had detailed inclusion and exclusion criteria. Demographic data were completely recorded in nineteen studies. The pancreatitis diagnostic criteria were not elaborate in nine studies only with abstracts and one study with full-test.


### 3.3. Prevalence of SVT in Pancreatitis

A meta-analysis of involved studies meeting eligibility criteria showed the prevalence of SVT in patients with pancreatitis, ranging from 0.5% to 62.1% (Figure2). A pooled prevalence was 13.6% (95% CI: 10.2%–17.4%) with a statistically significant heterogeneity among studies (I
2
=
96
.
2
%, 95% CI: 95.7%–96.6%, P
<
0.001).Figure 2
Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in pancreatitis.


### 3.4. Prevalence of PVT, SplVT, and MVT in Pancreatitis

Seventeen studies reported the prevalence of PVT in patients with pancreatitis, ranging from 0.2% to 62.1% (Figure3(a)). A pooled prevalence was 6.2% (95% CI: 32.9%–10.7%) with a statistically significant heterogeneity among studies (I
2 = 97.1%, 95% CI: 96.6%–97.6%, P
<
0.001). The analysis of patients with SplVT in pancreatitis showed that the prevalence ranged from 0.2% to 41.7% (Figure 3(b)). A pooled prevalence was 11.2% (95% CI: 8.1%–14.7%) with a statistically significant heterogeneity among studies (I
2 = 95.2%, 95% CI: 94.4%–95.8%, P
<
0.001). Eleven studies were selected to analyze the prevalence of MVT in pancreatitis, ranging from 0.3% to 14% (Figure 3(c)). The pooled prevalence was 2.7% (95% CI: 1.4%–4.4%) and the heterogeneity remained (I
2 = 89.3%, 95% CI: 83.2%–92.5%).Figure 3
(a) Forest plots showing the prevalence of portal vein thrombosis (PVT) in pancreatitis. (b) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in pancreatitis. (c) Forest plots showing the prevalence of mesenteric vein thrombosis (MVT) in pancreatitis.
(a)
(b)
(c)


### 3.5. Prevalence of SVT in AP and CP

Eighteen studies reported the prevalence of SVT in AP, ranging from 0.3% to 62.1% (Figure4(a)). The pooled prevalence was 16.6% (95% CI: 10.0%–24.5%) with a statistically significant heterogeneity among studies (I
2 = 98%, 95% CI: 97.7%–98.2%, P
<
0.001). Nine studies reported the prevalence of PVT in AP, ranging from 0.3% to 62.1% (Figure 4(b)). The pooled prevalence was 8.0% (95% CI: 2.4%–16.4%) with a statistically significant heterogeneity among studies (I
2 = 98.2%, 95% CI: 97.8%–98.5%, P
<
0.001). Fifteen studies reported the prevalence of SplVT in AP, ranging from 1.2% to 20% (Figure 4(c)). The pooled prevalence was 10.4% (95% CI: 6.3%–15.3%) with a statistically significant heterogeneity among studies (I
2 = 94.8%, 95% CI: 93.3%–95.8%, P
<
0.001). Eight studies reported the prevalence of MVT in pancreatitis, ranging from 0.3% to 14.0% (Figure 4(d)). The pooled prevalence was 2.6% (95% CI: 1.2%–4.5%) with a statistically significant heterogeneity among studies (I
2 = 90.4%, 95% CI: 83.9%–93.6%, P
<
0.001).Figure 4
(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in acute pancreatitis (AP). (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in acute pancreatitis (AP). (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in acute pancreatitis (AP). (d) Forest plots showing the prevalence of mesenteric vein thrombosis (MVT) in acute pancreatitis (AP).
(a)
(b)
(c)
(d)Twenty studies reported the prevalence of SVT in CP, ranging from 3% to 41.7% (Figure5(a)). The pooled prevalence was 11.6% (95% CI: 8.5%–15.1%) with a statistically significant heterogeneity among studies (I
2 = 89.5%, 95% CI: 85.6%–91.9%, P
<
0.001). Four studies reported the prevalence of PVT in CP, ranging from 1.5% to 4% (Figure 5(b)). The pooled prevalence was 3.5% (95% CI: 2.3%–4.8%) and there was no statistical heterogeneity between the two studies (I
2 = 0%, 95% CI: 0%–67.9%, P
=
0.5947). Thirteen studies reported the prevalence of SplVT in CP, ranging from 1.5% to 41.7% (Figure 5(c)). The pooled prevalence was 12.8% (95% CI: 8.7%–17.6%) with a statistically significant heterogeneity among studies (I
2 = 88.8%, 95% CI: 83%–91.9%, P
<
0.001). Two studies reported the prevalence of MVT in pancreatitis, ranging from 0.8% to 1.1% (Figure 5(d)). The pooled prevalence was 1.2% (95% CI: 0.4%–2.5%). There was no statistical heterogeneity between the two studies (P
=
0.8506).Figure 5
(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in chronic pancreatitis (CP). (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in chronic pancreatitis (CP). (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in chronic pancreatitis (CP). (d) Forest plots showing the prevalence of mesenteric vein thrombosis (MVT) in chronic pancreatitis (CP).
(a)
(b)
(c)
(d)


### 3.6. Prevalence of SVT in HP and AIP

Only two studies reported the prevalence of SVT in HP, ranging from 7% to 19% (Figure6(a)). The pooled prevalence was 12.2% (95% CI: 3.0%–26.5%) and there was no statistical heterogeneity between the two studies (P
=
0.0914). Two studies reported the prevalence of PVT in HP, ranging from 2.8% to 11.5% (Figure 6(b)). The pooled prevalence was 6.6% (95% CI: 0.7%–17.8%) and there was no statistical heterogeneity between the two studies (P
=
0.1056). Two studies reported the prevalence of SplVT in HP, ranging from 4.2% to 7.7% (Figure 6(c)). The pooled prevalence was 5.8% (95% CI: 2.1%–11.2%) and there was no statistical heterogeneity between the two studies (P
=
0.437). There was no data on the prevalence of MVT in HP.Figure 6
(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in hereditary pancreatitis (HP). (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in hereditary pancreatitis (HP). (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in hereditary pancreatitis (HP).
(a)
(b)
(c)Five studies reported the prevalence of SVT in AIP, ranging from 1.9% to 25% (Figure7(a)). The pooled prevalence was 14.6% (95% CI: 6.1%–25.9%) and there was no statistical heterogeneity between the two studies (I
2 = 71.4%, 95% CI: 0%–86.7%, P
=
0.0074). Two studies reported the prevalence of SplVT in AIP, ranging from 15% to 25% (Figure 7(b)). The pooled prevalence was 20.2% (95% CI: 9.8%–33.2%) and there was no statistical heterogeneity between the two studies (P
=
0.4388). Only one study reported that the prevalence of PVT in AIP was 1.9%. There was no data on the prevalence of MVT in AIP.Figure 7
(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in autoimmune pancreatitis (AIP). (b) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in autoimmune pancreatitis (AIP).
(a)
(b)


### 3.7. Prevalence of SVT in Pancreatitis in Different Continent

The involved countries of all studies could be divided into three continents (Europe, America, and Asia). The incidences of SVT in pancreatitis were different among three continents. In Europe, twenty-two studies reported the prevalence of pancreatitis patients with SVT, ranging from 0.5% to 62.1% (Figure8(a)). The pooled prevalence was 16.9% (95% CI: 10.7%–24.2%) with a statistically significant heterogeneity among studies (I
2 = 97%, 95% CI: 96.6%–97.4%, P
<
0.001). Nine studies reported the prevalence of PVT in pancreatitis, ranging from 0.2% to 62.1% (Figure 8(b)). The pooled prevalence was 8.5% (95% CI: 1.6%–19.9%) with a statistically significant heterogeneity among studies (I
2 = 98.1%, 95% CI: 97.7%–98.4%). Sixteen studies reported the prevalence of SplVT in pancreatitis, ranging from 0.2% to 31.9% (Figure 8(c)). The pooled prevalence was 13.5% (95% CI: 7.6%–20.9%) with a statistically significant heterogeneity among studies (I
2 = 96.2%, 95% CI: 95.3%–96.8%, P
<
0.001). Six studies reported the prevalence of MVT in pancreatitis, ranging from 0.3% to 10% (Figure 8(d)). The pooled prevalence was 3.2% (95% CI: 1.0%–6.8%) with a statistically significant heterogeneity among studies (I
2 = 88.8%, 95% CI: 77.4%–93.1%, P
<
0.001).Figure 8
(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in Europe. (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in Europe. (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in Europe. (d) Forest plots showing the prevalence of mesenteric vein thrombosis (MVT) in Europe.
(a)
(b)
(c)
(d)In America, fourteen studies reported the prevalence of SVT in pancreatitis, ranging from 1.6% to 46% (Figure9(a)). The pooled prevalence was 11.5% (95% CI: 7.0%–16.8%) with a statistically significant heterogeneity among studies (I
2 = 95.7%, 95% CI: 94.6%–96.5%, P
<
0.001). Five studies reported the prevalence of PVT in pancreatitis, ranging from 0.3% to 13% (Figure 9(b)). The pooled prevalence was 3.7% (95% CI: 1.3%–7.4%) with a statistically significant heterogeneity among studies (I
2 = 93.2%, 95% CI: 87.6%–95.6%, P
<
0.00
1). Thirteen studies reported the prevalence of SplVT in pancreatitis, ranging from 0.8% to 22% (Figure 9(c)). The pooled prevalence was 9.2% (95% CI: 5.5%–13.7%) with a statistically significant heterogeneity among studies (I
2 = 94.8%, 95% CI: 93.2%–95.9%, P
<
0.001). Five studies reported the prevalence of MVT in pancreatitis, ranging from 0.4% to 14% (Figure 9(d)). The pooled prevalence was 2.4% (95% CI: 0.7%–5.0%) with a statistically significant heterogeneity among studies (I
2 = 91.7%, 95% CI: 83.6%–94.8%, P
<
0.001).Figure 9
(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in America. (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in America. (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in America. (d) Forest plots showing the prevalence of mesenteric vein thrombosis (MVT) in America.
(a)
(b)
(c)
(d)In Asia, eight studies reported the prevalence of SVT in pancreatitis, ranging from 1.4% to 41.7% (Figure10(a)). The pooled prevalence was 8.5% (95% CI: 3.7%–15.1%) with a statistically significant heterogeneity among studies (I
2 = 84.2%, 95% CI: 68.5%–90.3%, P
<
0.001). Two studies reported the prevalence of PVT in pancreatitis, ranging from 1.8% to 1.9% (Figure 10(b)). The pooled prevalence in two studies was 2.3% (95% CI: 0.7%–4.6%). Six studies reported the prevalence of SplVT in pancreatitis, ranging from 1.4% to 41.7% (Figure 10(c)). The pooled prevalence was 10.1% (95% CI: 3.6%–19.5%) with a statistically significant heterogeneity among studies (I
2 = 87.8%, 95% CI: 74.5%–92.6%, P
<
0.001). There was no data on the prevalence of MVT in pancreatitis in Asia.Figure 10
(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in Asia. (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in Asia. (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in Asia.
(a)
(b)
(c)


## 3.1. Description of the Included Studies

In the initial search strategy, a total of 947 studies were selected. Among them, 714 studies were retrieved by removing duplicate research. Two additional unique references were found through reference lists of an original article and a review, respectively [5, 6]. One study as object of related comment was also identified [7]. Total of 44 studies were included in the meta-analysis (Figure 1). Additionally, five studies recorded by the same study team in different publications were excluded [8–12] and one study which concerned the same patients by the same first author in different publications was also excluded [13]. Another study was excluded because the number of participants was <10 [14]. Twenty-two of 44 studies were conducted in Europe [6, 15–35], fourteen in America [2, 5, 7, 36–46], and eight in Asia [47–54]. Among 10441 participants, 874 patients with SVT were screened. These patients included 197 patients with PVT, 525 with SplV, and 72 with MVT. The detailed characteristics of these included studies were shown in Table 1.Table 1
Overview of included studies.
Authors         (publication year)
Type of research
Country
Interval of enrolment
Eligibility criteria
Type of disease  (AP, CP,  HP, or AIP)
Number of total samples
SVT
PVT
SlpVT
MVT
Mean age (range years)
Female/male
Sisman et al.(2014) [19]
Retrospectivecohort study
Turkey
2007–2011
NA
CP
65
13
NA
13
NA
NA
14/51
Britton et al.(2014) [18]
Retrospectivecohort study
UK
1998–2012
Exclusion criteria: 46 cases were excluded from the final analysis as imaging reports made no comment on the portal venous system.
AP
145
90
90
NA
NA
56.1
NA
Talukdar et al.(2014) [47]
Prospective cohort study
India
August 2011 to October 2012
Inclusion criteria: patients over 18 yrs with a primary diagnosis of first episode of AP from August 2011 to October 2012, and prospectively followed for at least six months after discharge or till death; exclusion criteria were (1) recurrent AP; (2) patient who did not get a CT scan.
AP
163
12
3
9
NA
NA
40/123
Easler et al.(2014) [38]
Prospective  study
USA
June 2003 and April 2010
Inclusion criteria: SAP patients who were admitted with their first AP attack; exclusion criteria:  patients with a history of AP or CP.
AP
162
22
8
19
6
55  ± 20
78/84
Castiñeira-Alvariño et al.(2013) [20]
Prospective study
Spain
Since 2007
Inclusion criteria: patients with age <18 years at index visit to the CP outpatient clinic; exclusion criteria: patients who clearly modified the diet before the index visit were excluded.
CP
168
5
5
NA
NA
44  (17–76)
40/128
Suero et al.(2013) [21]
Retrospective study
Spain
NA
NA
AIP
25
6
NA
NA
NA
(17–79)
2/23
Marra-López et al.(2013) [22]
Prospective  cohort study
Spain
2011–2013
Inclusion criteria: CP patients defined by M-ANNHEIM.
CP
85
9
NA
9/85
NA
59.38
17/68
Harris et al.(2013) [2]
Retrospective study
USA
January 1996 to December 2006
Inclusion criteria: an institutional  (Mayo clinic) database search was done using the key terms acute pancreatitis and superior mesenteric vein thrombosis  (SMVT), portal vein thrombosis  (PVT), and splenic vein thrombosis  (SplVT) from January 1996 to December 2006; exclusion criteria: (1) patients with precipitating factors for thrombosis  (abdominal surgery unrelated to ongoing pancreatitis, trauma, pregnancy, cirrhosis, intra-abdominal infections, pancreatic cancer, and primary myeloproliferative disorders) were excluded. (2) All cases of chronic pancreatitis were also excluded.
AP
2454
45
20
30
17
NA
NA
Jakchairoongruang and Arjhansiri(2013) [48]
Retrospective study
Thailand
January 1, 2005 and April 30, 2010
Exclusion criteria: six hundred and eight patients were excluded from the study population because of the following reasons: it was not the first episode of acute pancreatitis, the initial CT was not performed, there are no available CT images on our Pictures Archiving and Communications System  (PACS), or patient was imaged with only unenhanced CT.
AP
72
1
NA
1/72
NA
47.7 (6–89)
33/39
Ishikawa et al. (2012) [49]
Retrospective study
Japan
July 2003 and October 2010
Inclusion criteria: patients who met the International Consensus Diagnostic Criteria  (ICDC) for AIP.
AIP
54
1
1
NA
NA
63.2  ± 13.5  (28–86)
6/48
Sisman et al.(2012) [24]
Retrospective study
Turkey
2007–2011
Exclusion criteria: patients who received previous H. pylori eradication treatment and who are with any malignancy were excluded.
CP
64
11
NA
11
NA
NA
NA
De León et al.(2012) [25]
Retrospective study
Spain
NA
NA
AIP
16
4
NA
4
NA
46.6       (17–73)
1/15
Vyas et al.(2012) [23]
Retrospective study
UK
NA
NA
AP
87
22
NA
12
NA
NA
35/52
Muddana et al.(2012) [39]
Prospective  study
USA
2003–2010
NA
AP
251
41
NA
35
NA
51.5   ± 19
123/128
Rebours et al.(2012) [17]
Prospective single-center  study
France
2000–2009
Included criteria: all of the in- or outpatients with recurrent acute or chronic alcoholic pancreatitis and followed prospectively based on a standardized protocol, including a yearly physical examination and a search for exocrine pancreatic insufficiency, diabetes, and cholestasis; excluded criteria: (1) cirrhosis; (2) patients who were lost to follow-up in 2009.
AP or CP
119
41
14
38
10
NA
19/100
Gonzelez et al.(2011) [15]
Retrospective study
UK
January 1, 2008, and December 31, 2009
Excluded criteria: patients with chronic pancreatitis, known malignancy, cirrhosis, or established portal hypertension.
AP
127
20
10
14
3
53.5              (36–81)
118/9
Shalimar et al.(2011) [36]
Prospective  study
USA
NA
Inclusion criteria: patients with CP after an informed consent and ethical clearance; exclusion criteria: NA.
CP
226
9
NA
9
NA
NA
48/178
Huggett et al.(2011) [16]
Prospective  study
UK
2004–2010
Inclusion criteria: patients with AIP and with a median follow-up from diagnosis of 32 months  (range 0–76)
AIP
52
7
NA
NA
NA
59  (26–85)
11/41
Chowdhury et al.(2011) [50]
Retrospective study
India
January 2005 and December 2009
Inclusion criteria: children diagnosed with chronic pancreatitis  (on imaging study).
CP
73
4
NA
NA
NA
NA
22/51
Chooklin and Hranat (2009) [26]
Retrospective study
Ukraine
NA
NA
AP
20
4
NA
4
NA
NA
3/17
Vege et al.(2009) [37]
Retrospective study
USA
1989–2007
Exclusion criteria: patients with preexisting portal hypertension were excluded.
AP
1155
50
3
29
4
NA
NA
Keck et al.(2009) [27]
Retrospective study
Germany
In Germany: 2001–2005; in USA: 1995–2005
Excluded criteria: three patients whose predominant lesion was only a very dilated pancreatic duct and who were thus selected for lateral pancreaticojejunostomy.
CP
93
14
NA
14
NA
NA
31/62
Raina  et al.(2009) [5]
Retrospective study
USA
1998–2007
Exclusion criteria: three other malignancies (gastric cancer, the recurrence of gastric adenocarcinoma, and pancreatic adenocarcinoma).
AIP
26
4
NA
4
NA
62.5             (23–86)
9/17
Agarwal et al.(2008) [51]
Retrospective study
India
January 1996 and December 2005
NA
CP
157
34
NA
34
NA
NA
NA
Mortelé et al.(2004) [40]
Retrospective study
USA
17-month period
NA
AP
100
46
13
19
14
51             (12–80)
47/53
Makowiec et al.(2004) [28]
Prospective  study
Germany
1994–2001
Exclusion criteria: 12 patients with portal hypertension and 9 patients underwent splenectomy without splenic vein thrombosis.
CP
177
NA
NA
39
NA
NA
NA
Pimentel et al.(2003) [41]
Retrospective study
Brazil
1989–2002
NA
CP
64
2
NA
NA
NA
NA
14/50
Malíková et al.(2002) [29]
Retrospective study
Czech Republic
NA
NA
AP
40
NA
2
7
4
NA
NA
Mortelé et al.(2001) [42]
Retrospective study
USA
April 1996 and August 1997
NA
AP
100
19
NA
19
NA
NA
47/53
Sakorafas et al.(2000) [43]
Prospective  study
USA
1976–1997
NA
CP
484
34
NA
34
NA
NA
NA
Dörffel et al.(2000) [30]
Prospective  study
Germany
38 months
Included criteria: definite diagnosis of acute pancreatitis as detected by ultrasonography  (US) and CT, elevated serum lipase and amylase, compatible clinical picture, onset of pain symptoms not more than 3 days before admission, no history of pancreatitis, and no deficiencies in antithrombin III, protein C, and protein S.
AP
189
45
11
28
6
43             (19–80)
49/140
Arotcarena et al.(1999) [31]
Prospective  study
France
April 1993 to April 1996
NA
CP
494
73
NA
NA
NA
NA
NA
Tsushima et al.(1999) [52]
Retrospective study
Japan
April 1993 and August 1997
Included criteria: patients with AP  underwent initial abdominal CT within 3 days after the onset of symptoms and received at least one additional CT examination thereafter; Excluded criteria: cases of traumatic or postoperative pancreatitis
AP
25
1
NA
1
NA
53.4  ± 20.8                 (25–83)
7/18
Takase et al.(1997) [54]
Prospective  study
Japan
During the past 10 years
Exclusion criteria: 6 patients underwent pancreatoduodenectomy or biopsy without the splenic vein specimens
CP
12
5
NA
5
NA
48.8
0/12
Friess et al.(1997) [32]
Retrospective study
Greece
NA
NA
CP
397
21
NA
NA
NA
NA
NA
Lin et al.(1997) [53]
Prospective  study
Taiwan
1976–1996
NA
CP
90
5
NA
5
NA
NA
NA
Bernades et al.(1992) [6]
Prospective  longitudinal  Study
France
January  1980 and  March  1990
Inclusion criteria: patients who  met  the  criteria  of  CP and who had  been followed-up during observation; exclusion criteria: patients with cirrhosis.
CP
266
35
10
22
3
40.5              (6–77)
35/231
Nordback et al.  (1989) [35]
Retrospective study
Finland
1972–1986
NA
AP or CP
1268
6
2
2
4
NA
NA
Rogers and Klatt(1989) [44]
Retrospective  autopsy case-control  study
USA
January  1958  and  December  1987
Inclusion criteria: cases were included for  study if acute pancreatitis  was the  immediate or contributing cause  of  death  and  the  portal  venous  system   (both  splenic  and  portal  veins) was  examined  completely  at  autopsy. Exclusion criteria: patients  were  excluded  from  study  if there  had  been  a  splenectomy  or  if  chronic  pancreatitis  was  present  microscopically.
AP
72
11
NA
11
NA
NA
20/52
Hofer et al.(1987) [45]
Prospective  study
USA
1975–1985
NA
CP
50
11
NA
11
NA
50             (13–75)
24/26
Roesch et al.(1981) [33]
Retrospective study
Germany
NA
NA
CP
531
27
NA
27
NA
42.5
49/482
Sibert  (1978) [34]
Retrospective study
UK
NA
NA
HP
72
5
2
3
NA
NA
NA
McElroy and Christiansen(1972) [46]
Retrospective study
USA
NA
NA
HP
26
5
3
2
NA
NA
NA
Gross  (1958) [7]
Prospective  study
USA
1956
NA
AP or CP
125
2
NA
1
1
49              (6–75)
34/91
NA: the data are not available; AP: acute pancreatitis; CP: chronic pancreatitis; HP: hereditary pancreatitis; AIP: autoimmune pancreatitis; SVT: splanchnic vein thrombosis; PVT: portal vein thrombosis; SlpVT: splenic vein thrombosis; MVT: mesenteric vein thrombosis.Figure 1
Flow diagram of study selection.


## 3.2. Quality of the Included Studies

The involved countries of all studies could be found. Interval of enrolment was unavailable in ten of the 44 studies. Twenty-one studies had no eligibility criteria; eight of the remaining 23 studies had detailed inclusion and exclusion criteria. Demographic data were completely recorded in nineteen studies. The pancreatitis diagnostic criteria were not elaborate in nine studies only with abstracts and one study with full-test.


## 3.3. Prevalence of SVT in Pancreatitis

A meta-analysis of involved studies meeting eligibility criteria showed the prevalence of SVT in patients with pancreatitis, ranging from 0.5% to 62.1% (Figure2). A pooled prevalence was 13.6% (95% CI: 10.2%–17.4%) with a statistically significant heterogeneity among studies (I
2
=
96
.
2
%, 95% CI: 95.7%–96.6%, P
<
0.001).Figure 2
Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in pancreatitis.


## 3.4. Prevalence of PVT, SplVT, and MVT in Pancreatitis

Seventeen studies reported the prevalence of PVT in patients with pancreatitis, ranging from 0.2% to 62.1% (Figure3(a)). A pooled prevalence was 6.2% (95% CI: 32.9%–10.7%) with a statistically significant heterogeneity among studies (I
2 = 97.1%, 95% CI: 96.6%–97.6%, P
<
0.001). The analysis of patients with SplVT in pancreatitis showed that the prevalence ranged from 0.2% to 41.7% (Figure 3(b)). A pooled prevalence was 11.2% (95% CI: 8.1%–14.7%) with a statistically significant heterogeneity among studies (I
2 = 95.2%, 95% CI: 94.4%–95.8%, P
<
0.001). Eleven studies were selected to analyze the prevalence of MVT in pancreatitis, ranging from 0.3% to 14% (Figure 3(c)). The pooled prevalence was 2.7% (95% CI: 1.4%–4.4%) and the heterogeneity remained (I
2 = 89.3%, 95% CI: 83.2%–92.5%).Figure 3
(a) Forest plots showing the prevalence of portal vein thrombosis (PVT) in pancreatitis. (b) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in pancreatitis. (c) Forest plots showing the prevalence of mesenteric vein thrombosis (MVT) in pancreatitis.
(a)
(b)
(c)


## 3.5. Prevalence of SVT in AP and CP

Eighteen studies reported the prevalence of SVT in AP, ranging from 0.3% to 62.1% (Figure4(a)). The pooled prevalence was 16.6% (95% CI: 10.0%–24.5%) with a statistically significant heterogeneity among studies (I
2 = 98%, 95% CI: 97.7%–98.2%, P
<
0.001). Nine studies reported the prevalence of PVT in AP, ranging from 0.3% to 62.1% (Figure 4(b)). The pooled prevalence was 8.0% (95% CI: 2.4%–16.4%) with a statistically significant heterogeneity among studies (I
2 = 98.2%, 95% CI: 97.8%–98.5%, P
<
0.001). Fifteen studies reported the prevalence of SplVT in AP, ranging from 1.2% to 20% (Figure 4(c)). The pooled prevalence was 10.4% (95% CI: 6.3%–15.3%) with a statistically significant heterogeneity among studies (I
2 = 94.8%, 95% CI: 93.3%–95.8%, P
<
0.001). Eight studies reported the prevalence of MVT in pancreatitis, ranging from 0.3% to 14.0% (Figure 4(d)). The pooled prevalence was 2.6% (95% CI: 1.2%–4.5%) with a statistically significant heterogeneity among studies (I
2 = 90.4%, 95% CI: 83.9%–93.6%, P
<
0.001).Figure 4
(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in acute pancreatitis (AP). (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in acute pancreatitis (AP). (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in acute pancreatitis (AP). (d) Forest plots showing the prevalence of mesenteric vein thrombosis (MVT) in acute pancreatitis (AP).
(a)
(b)
(c)
(d)Twenty studies reported the prevalence of SVT in CP, ranging from 3% to 41.7% (Figure5(a)). The pooled prevalence was 11.6% (95% CI: 8.5%–15.1%) with a statistically significant heterogeneity among studies (I
2 = 89.5%, 95% CI: 85.6%–91.9%, P
<
0.001). Four studies reported the prevalence of PVT in CP, ranging from 1.5% to 4% (Figure 5(b)). The pooled prevalence was 3.5% (95% CI: 2.3%–4.8%) and there was no statistical heterogeneity between the two studies (I
2 = 0%, 95% CI: 0%–67.9%, P
=
0.5947). Thirteen studies reported the prevalence of SplVT in CP, ranging from 1.5% to 41.7% (Figure 5(c)). The pooled prevalence was 12.8% (95% CI: 8.7%–17.6%) with a statistically significant heterogeneity among studies (I
2 = 88.8%, 95% CI: 83%–91.9%, P
<
0.001). Two studies reported the prevalence of MVT in pancreatitis, ranging from 0.8% to 1.1% (Figure 5(d)). The pooled prevalence was 1.2% (95% CI: 0.4%–2.5%). There was no statistical heterogeneity between the two studies (P
=
0.8506).Figure 5
(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in chronic pancreatitis (CP). (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in chronic pancreatitis (CP). (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in chronic pancreatitis (CP). (d) Forest plots showing the prevalence of mesenteric vein thrombosis (MVT) in chronic pancreatitis (CP).
(a)
(b)
(c)
(d)


## 3.6. Prevalence of SVT in HP and AIP

Only two studies reported the prevalence of SVT in HP, ranging from 7% to 19% (Figure6(a)). The pooled prevalence was 12.2% (95% CI: 3.0%–26.5%) and there was no statistical heterogeneity between the two studies (P
=
0.0914). Two studies reported the prevalence of PVT in HP, ranging from 2.8% to 11.5% (Figure 6(b)). The pooled prevalence was 6.6% (95% CI: 0.7%–17.8%) and there was no statistical heterogeneity between the two studies (P
=
0.1056). Two studies reported the prevalence of SplVT in HP, ranging from 4.2% to 7.7% (Figure 6(c)). The pooled prevalence was 5.8% (95% CI: 2.1%–11.2%) and there was no statistical heterogeneity between the two studies (P
=
0.437). There was no data on the prevalence of MVT in HP.Figure 6
(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in hereditary pancreatitis (HP). (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in hereditary pancreatitis (HP). (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in hereditary pancreatitis (HP).
(a)
(b)
(c)Five studies reported the prevalence of SVT in AIP, ranging from 1.9% to 25% (Figure7(a)). The pooled prevalence was 14.6% (95% CI: 6.1%–25.9%) and there was no statistical heterogeneity between the two studies (I
2 = 71.4%, 95% CI: 0%–86.7%, P
=
0.0074). Two studies reported the prevalence of SplVT in AIP, ranging from 15% to 25% (Figure 7(b)). The pooled prevalence was 20.2% (95% CI: 9.8%–33.2%) and there was no statistical heterogeneity between the two studies (P
=
0.4388). Only one study reported that the prevalence of PVT in AIP was 1.9%. There was no data on the prevalence of MVT in AIP.Figure 7
(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in autoimmune pancreatitis (AIP). (b) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in autoimmune pancreatitis (AIP).
(a)
(b)


## 3.7. Prevalence of SVT in Pancreatitis in Different Continent

The involved countries of all studies could be divided into three continents (Europe, America, and Asia). The incidences of SVT in pancreatitis were different among three continents. In Europe, twenty-two studies reported the prevalence of pancreatitis patients with SVT, ranging from 0.5% to 62.1% (Figure8(a)). The pooled prevalence was 16.9% (95% CI: 10.7%–24.2%) with a statistically significant heterogeneity among studies (I
2 = 97%, 95% CI: 96.6%–97.4%, P
<
0.001). Nine studies reported the prevalence of PVT in pancreatitis, ranging from 0.2% to 62.1% (Figure 8(b)). The pooled prevalence was 8.5% (95% CI: 1.6%–19.9%) with a statistically significant heterogeneity among studies (I
2 = 98.1%, 95% CI: 97.7%–98.4%). Sixteen studies reported the prevalence of SplVT in pancreatitis, ranging from 0.2% to 31.9% (Figure 8(c)). The pooled prevalence was 13.5% (95% CI: 7.6%–20.9%) with a statistically significant heterogeneity among studies (I
2 = 96.2%, 95% CI: 95.3%–96.8%, P
<
0.001). Six studies reported the prevalence of MVT in pancreatitis, ranging from 0.3% to 10% (Figure 8(d)). The pooled prevalence was 3.2% (95% CI: 1.0%–6.8%) with a statistically significant heterogeneity among studies (I
2 = 88.8%, 95% CI: 77.4%–93.1%, P
<
0.001).Figure 8
(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in Europe. (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in Europe. (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in Europe. (d) Forest plots showing the prevalence of mesenteric vein thrombosis (MVT) in Europe.
(a)
(b)
(c)
(d)In America, fourteen studies reported the prevalence of SVT in pancreatitis, ranging from 1.6% to 46% (Figure9(a)). The pooled prevalence was 11.5% (95% CI: 7.0%–16.8%) with a statistically significant heterogeneity among studies (I
2 = 95.7%, 95% CI: 94.6%–96.5%, P
<
0.001). Five studies reported the prevalence of PVT in pancreatitis, ranging from 0.3% to 13% (Figure 9(b)). The pooled prevalence was 3.7% (95% CI: 1.3%–7.4%) with a statistically significant heterogeneity among studies (I
2 = 93.2%, 95% CI: 87.6%–95.6%, P
<
0.00
1). Thirteen studies reported the prevalence of SplVT in pancreatitis, ranging from 0.8% to 22% (Figure 9(c)). The pooled prevalence was 9.2% (95% CI: 5.5%–13.7%) with a statistically significant heterogeneity among studies (I
2 = 94.8%, 95% CI: 93.2%–95.9%, P
<
0.001). Five studies reported the prevalence of MVT in pancreatitis, ranging from 0.4% to 14% (Figure 9(d)). The pooled prevalence was 2.4% (95% CI: 0.7%–5.0%) with a statistically significant heterogeneity among studies (I
2 = 91.7%, 95% CI: 83.6%–94.8%, P
<
0.001).Figure 9
(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in America. (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in America. (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in America. (d) Forest plots showing the prevalence of mesenteric vein thrombosis (MVT) in America.
(a)
(b)
(c)
(d)In Asia, eight studies reported the prevalence of SVT in pancreatitis, ranging from 1.4% to 41.7% (Figure10(a)). The pooled prevalence was 8.5% (95% CI: 3.7%–15.1%) with a statistically significant heterogeneity among studies (I
2 = 84.2%, 95% CI: 68.5%–90.3%, P
<
0.001). Two studies reported the prevalence of PVT in pancreatitis, ranging from 1.8% to 1.9% (Figure 10(b)). The pooled prevalence in two studies was 2.3% (95% CI: 0.7%–4.6%). Six studies reported the prevalence of SplVT in pancreatitis, ranging from 1.4% to 41.7% (Figure 10(c)). The pooled prevalence was 10.1% (95% CI: 3.6%–19.5%) with a statistically significant heterogeneity among studies (I
2 = 87.8%, 95% CI: 74.5%–92.6%, P
<
0.001). There was no data on the prevalence of MVT in pancreatitis in Asia.Figure 10
(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in Asia. (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in Asia. (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in Asia.
(a)
(b)
(c)


## 4. Discussion

The previous published meta-analysis that assessed the prevalence of SVT in patients with pancreatitis almost focused on AP, CP, HP, or AIP alone without systematic search. The prevalence varied from 1% to 24% in previous studies according to the type of pancreatitis and imaging technique used (US, EUS, CT, MRI, or ERCP) [30, 40, 55]. However, our study was remarkably different from the previous ones, as follows. (1) In the previous studies, most of them were single-center studies with a limited enrollment period and target population. By comparison, our meta-analysis included all studies conducted from 1958 to 2014 and 10560 patients with pancreatitis. Furthermore, we made a distinction on the source of patients according to the continents. (2) As we have known, SVT involves PVT, SplVT, and MVT. In contrast to the previous studies, we have paid more attention on the prevalence of PVT, SplVT, and MVT in pancreatitis. (3) Our research reported the prevalence of SVT on the basis of the different types of pancreatitis including AP, CP, HP, and AIP. However, there was no similar record in the previous studies.Pancreatitis is associated with a variety of vascular complications including SVT. Clinically, SVT in pancreatitis is becoming common with the advancement of imaging technique. In the current systematic review and meta-analysis, we demonstrated that 13.6% of pancreatitis had SVT, 6.2% had PVT, 11.2% had SplVT, and 2.7% had MVT. The prevalence of SVT in pancreatitis showed some regional differences. We found that the prevalence of SVT in pancreatitis in Europe reached 16.9%, which was the highest among the three continents. Moreover, the prevalence of PVT, SplVT, and MVT in pancreatitis in Europe was higher than that in America or in Asia, respectively. We can find from the involved studies that the results came from nine countries of Europe, which were more than those from four of Asia and two of America. Compared with Asia, the prevalence of SVT in pancreatitis was 11.5% higher than that of 8.5% in Asia, but the prevalence of SplVT was a little lower in America.Previous studies that reported the vascular complications of pancreatitis showed different prevalence of SVT in pancreatitis regardless of the type of pancreatitis. This meta-analysis demonstrated that the prevalence of SVT in AP was 16.6% higher than previous studies with a reported incidence of 1-2%  [1]. The reason was that previous studies took PVT, SplVT, and MVT inclusion of SVT as numerator. The controversy also exists about the prevalence of SplVT in CP. The old series reported that the prevalence of SplVT in patients with CP varied between 2.5% and 25% [6, 51, 56, 57]. Our results showed 12.8% CP with SplVT, which was similar to that from a recent report by Butler et al. [58]. However, there was no detailed description on the prevalence of SVT in HP and AIP. Our results showed that the prevalence of SVT was 12.2% and 14.6% in HP and AIP, respectively. All of these could enrich the whole research on the prevalence of SVT in pancreatitis.


## 5. Limitation

Our study has several limitations. Firstly, the heterogeneity of available data from various years’ studies was significant. Depending on advanced imaging technique, the majority of asymptomatic patients with SVT could be involved in research groups. Therefore, only the random-effects model was applied in our meta-analysis to generate a more conservative estimate of the proportion. Secondly, there are different results between Western and Asian countries. Besides the difference in the population race, lifestyle, and diagnostic level, the number of countries involved in the research is different. America included two countries and four countries were from Asia. Thirdly, there is no related research on the prevalence of SVT in HP and AIP. The final results may be not so typical.


## 6. Conclusion

This systematic review and meta-analysis attempt to quantify the incidence of SVT in pancreatitis according to the different forms of pancreatitis and regional distribution. Further studies are needed to analyze the relationship between natural history, clinical significance, long-term outcomes, and the prevalence of SVT in pancreatitis. The rate of SVT associated gastrointestinal bleeding and the security and reasonability of anticoagulation therapy on thrombosis are all needed to develop complete, large, multicentre, and collaborative studies.



---

*Source: 245460-2015-09-14.xml*